Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy.
Schwarz M, Schwarz C, Schütz A, Schwanke C, Krabb E, Schubert R, Liebich ST, Bauer D, Burghart L, Brinkmann L, Gutic E, Reiberger T, Haltmayer H, Gschwantler M. Schwarz M, et al. Among authors: gutic e. J Virus Erad. 2023 Mar 2;9(1):100319. doi: 10.1016/j.jve.2023.100319. eCollection 2023 Mar. J Virus Erad. 2023. PMID: 36970063 Free PMC article.
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M. Moser S, et al. Among authors: gutic e. Eur J Gastroenterol Hepatol. 2018 Mar;30(3):291-295. doi: 10.1097/MEG.0000000000001027. Eur J Gastroenterol Hepatol. 2018. PMID: 29120906
Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Schmidbauer C, et al. Among authors: gutic e. PLoS One. 2020 Mar 10;15(3):e0229239. doi: 10.1371/journal.pone.0229239. eCollection 2020. PLoS One. 2020. PMID: 32155165 Free PMC article.
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
Schmidbauer C, Schwarz M, Schütz A, Schubert R, Schwanke C, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Schmidbauer C, et al. Among authors: gutic e. PLoS One. 2021 Jun 4;16(6):e0252274. doi: 10.1371/journal.pone.0252274. eCollection 2021. PLoS One. 2021. PMID: 34086708 Free PMC article.